Phase 2

Letermovir for CMV Prevention After Lung Transplantation

Sponsor:

Fernanda P Silveira, MD, MS

Code:

NCT05041426

Conditions

Lung Transplant

CMV

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Not accepted

Interventions

Letermovir

Valganciclovir

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information